Alembic Pharmaceuticals Receives USFDA Tentative Approval for Darolutamide Tablets
1 hour agoBusiness
34LENS
2 SourcesIndia
TBNthebalanced.news

Alembic Pharmaceuticals Receives USFDA Tentative Approval for Darolutamide Tablets

Alembic Pharmaceuticals has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Darolutamide Tablets, 300 mg. This drug, equivalent to Bayer's Nubeqa Tablets, is used to treat various forms of prostate cancer. The approval adds to Alembic's total of 238 USFDA ANDA approvals. Darolutamide's market size is estimated at $3.155 billion through March 2026. Alembic recently reported a slight profit decline despite increased sales in Q3 FY26.

Political Bias
0%100%0%
Sentiment
72%
AI analysis of 2 sources · Published under editorial oversight by The Balanced News
Analysed 14 May 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 2 sources
● Left 0%● Center 100%● Right 0%

The articles present a straightforward business and regulatory update without political framing. Coverage focuses on Alembic Pharmaceuticals' regulatory milestone and financial performance, reflecting corporate and market perspectives. There is no evident political viewpoint or partisan interpretation in the reporting.

Sentiment — Positive (72/100)

The tone across the articles is neutral to mildly positive, emphasizing the regulatory approval as a business achievement. While noting a slight profit decline, the overall sentiment highlights growth potential and market opportunity without overt optimism or criticism.

How 2 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

SourceTheir headlineBiasSentiment
businessstandardAlembic Pharmaceuticals receives USFDA approval for Darolutamide Tablets, 300 mgCenterPositive
businessstandardAlembic Pharma gains after receiving USFDA nod for Darolutamide tabletsCenterPositive

Coverage timeline

businessstandard broke this story on 14 May, 05:59 am. Other outlets followed.

  1. 1
    businessstandard14 May, 05:59 am
    Alembic Pharma gains after receiving USFDA nod for Darolutamide tablets
  2. 2
    businessstandard14 May, 06:12 am
    Alembic Pharmaceuticals receives USFDA approval for Darolutamide Tablets, 300 mg

Lens Score breakdown

34/100
Public interest0/100
Coverage gap100%

Well-covered story — coverage matches public importance.

Who's involved

Institutions and figures named across source coverage.

Corporate
Bayer HealthCare Pharmaceuticals Inc.Bayer HealthCare PharmaceuticalsUS Food and Drug AdministrationAlembic Pharmaceuticals

Story context

Category
Business
Location
India
Sources analysed
2
Last analysed
14 May 2026
Key entities
DarolutamideAbbreviated New Drug ApplicationFood and Drug AdministrationAlembic PharmaceuticalsProstate cancerDocetaxelAndrogen receptorMetastasisEnzyme inhibitorBayerNew drug applicationAlembic